One-in-ten hypertension cases is treatment resistant (ie, inadequate response with 3 or more antihypertensives). While renal denervation has proven safe for treating severe hypertension, the latest results from SYMPLICITY HTN-3 render its efficacy unclear. Patient selection remains one of the biggest challenges, as 20% of patients are non-responders in clinical trials. At ACC 2014, SYMPLICITY HTN-3 primary results and the Global SYMPLICITY registry, which looks at post-approval real-world outcomes on multiple continents, were presented. This webcast will review key results. A panel discussion will provide context for the SYMPLICITY HTN-3 and GLOBAL SYMPLICITY results and implications for the field of renal denervation.
Click Here to access this CME Program
June 16th, 2014
December 16th, 2014